Other
Payments to Acquire Debt Securities, Available-for-Sale
Alnylam Pharmaceuticals Payments to Acquire Debt Securities, Available-for-Sale increased by 10.9% to $261.63M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.9%, from $401.64M to $261.63M. Over 4 years (FY 2021 to FY 2025), Payments to Acquire Debt Securities, Available-for-Sale shows a downward trend with a -5.8% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Higher outflows indicate active investment in fixed-income assets, often driven by premium growth or capital deployment strategies.
Detailed definition
Represents the cash outflows used to purchase debt securities classified as available-for-sale. This reflects the compan...
Peer comparison
Standard for institutional investors and insurance companies managing float.
Metric ID:
other_payments_to_acquire_available_for_sale_securities_debtHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $168.86M | $458.33M | $682.97M | $634.71M | $461.57M | $157.31M | $723.38M | $435.75M | $377.14M | $421.46M | $589.16M | $420.12M | $297.71M | $430.38M | $486.71M | $401.64M | $459.56M | $207.97M | $235.91M | $261.63M |
| QoQ Change | — | +171.4% | +49.0% | -7.1% | -27.3% | -65.9% | +359.8% | -39.8% | -13.4% | +11.8% | +39.8% | -28.7% | -29.1% | +44.6% | +13.1% | -17.5% | +14.4% | -54.7% | +13.4% | +10.9% |
| YoY Change | — | — | — | — | +173.3% | -65.7% | +5.9% | -31.3% | -18.3% | +167.9% | -18.6% | -3.6% | -21.1% | +2.1% | -17.4% | -4.4% | +54.4% | -51.7% | -51.5% | -34.9% |
Range$157.31M – $723.38M
CAGR+9.7%
Avg YoY Growth+5.3%
Median YoY Growth-17.8%
Current Streak2 quarters growth
Payments to Acquire Debt Securities, Available-for-Sale at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's payments to acquire debt securities, available-for-sale?
- Alnylam Pharmaceuticals (ALNY) reported payments to acquire debt securities, available-for-sale of $261.63M in Q1 2026.
- How has Alnylam Pharmaceuticals's payments to acquire debt securities, available-for-sale changed year-over-year?
- Alnylam Pharmaceuticals's payments to acquire debt securities, available-for-sale decreased by 34.9% year-over-year, from $401.64M to $261.63M.
- What is the long-term trend for Alnylam Pharmaceuticals's payments to acquire debt securities, available-for-sale?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's payments to acquire debt securities, available-for-sale has grown at a -5.8% compound annual growth rate (CAGR), from $1.66B to $1.31B.
- What does payments to acquire debt securities, available-for-sale mean?
- Cash spent to purchase debt securities intended for investment.